Page 10 - Best oncologists: TOP 650 doctors

Prof. Zvi Ram is a top neurosurgeon and head of the European Association of Neurosurgical Societies (EANS). He specializes in disorders of the brain and spinal cord, such as aneurysms, brain tumors, and Parkinson's Disease. He has received numerous awards for his innovative approach to neurology treatments and research, and is an expert in neurosurgical operations with brain mapping and deep brain stimulation.

Education and Specialization

2017 Istanbul University Istanbul Faculty of Medicine, Department of Internal Medicine, Department of Internal Medicine

19 November 2020 Istanbul University Istanbul Faculty of Medicine, Department of Medical Oncology

2011-25 June 2015 Hospitals / Istanbul Haydarpasa Numune Education and Research Hospital

2004 Mersin University Faculty of Medicine

Experience

13.11.2017-29.03.2021 Istanbul University Istanbul Faculty of Medicine Internal Medicine Departments, Department of Internal Medicine

21.03.2011-25.06.2015 Istanbul Haydarpasa Numune Education and Research Hospital



Ferhatoğlu Ferhat, Çağatay Tulin, Okumuş Nigar Gülfer, Aydıner Adnan, Paksoy Nail, Ak Naziye, Aydın Esra, Saip Pinar Mualla (2023). Laterality Of Adrenal Gland Metastasis In Lung Cancer: Results Of A Comparative Study. Eurasian Journal Of Medical Investigatin, 7(2), 101-106., Doi: 10.14744/Ejmi.2023.58954

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

FERHATOĞLU FERHAT, PAKSOY NAİL, BAŞARAN MERT (2022). Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center. Namık Kemal Medical Journal, 10(4), 350-356., Doi: 10.4274/nkmj.galenos.2022.78942

TAŞTEKİN DİDEM, PAKSOY NAİL, DOĞAN İZZET, FERHATOĞLU FERHAT, KHANMAMMADOV NIJAT, BOZBEY HAMZA UGUR, KARABULUT SENEM (2023). Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first?line treatment of metastatic gastric cancer: A single?center experience. Journal of Cancer Research and Therapeutics, 19(2), 253-258., Doi: 10.4103/jcrt.jcrt_672_22 (Quarterly=Q4)

KAPAĞAN TANJU, FERHATOĞLU FERHAT (2023). Prognostic Factors for Intensive Care Unit (ICU) Admission among Hospitalized Gastrointestinal and Hepatopancreatobiliary Cancer Patients with Systemic Urinary Tract Infection. Eurasian Journal of Medical Investigation, 7(2), 107-115., Doi: 10.14744/ejmi.2023.81340

KAPAĞAN TANJU, FERHATOĞLU FERHAT (2023). Prognostic Factors for Intensive Care Unit (ICU) Admission among Hospitalized Gastrointestinal and Hepatopancreatobiliary Cancer Patients with Systemic Urinary Tract Infection. Eurasian Journal of Medical Investigation, 7(2), 107-115., Doi: 10.14744/ejmi.2023.81340

FERHATOĞLU FERHAT, AYDINER ADNAN, PAKSOY NAİL (2022). Evaluation of clinical features and risk factors related to late recurrence (>5 years) in patients with breast cancer. Journal of Surgery and Medicine, 6(12), 986-990., doi: 10.28982/josam.7610

FERHATOĞLU FERHAT, ERTÜRK KAYHAN, TAŞ FARUK (2022). Cutaneous melanoma survival rates of the elderly are not worse than those of the young, yet they have some specific differences. Journal of Cancer Research and Therapeutics, 0, Doi: 10.4103/jcrt.jcrt_815_21

ÖZGÜR EMRE, FERHATOĞLU FERHAT, ŞEN FATMA, GEZER UĞUR (2022). Effect of Cytotoxic Therapy on ALU Expression is Modulated by Hormonal Status in Patients with Breast Cancer. BALKAN MEDICAL JOURNAL, 39(6), 450-451., Doi: 10.4274/balkanmedj.galenos.2022.2022-5-18

Articles

TAŞ FARUK, ERTÜRK KAYHAN, FERHATOĞLU FERHAT (2022). Auricular and periauricular melanomas have similar clinicopathologic factors and survival rates. JOURNAL OF COSMETIC DERMATOLOGY, 21(4), 1570-1573., Doi: 10.1111/jocd.14278

TAŞ FARUK, ERTÜRK KAYHAN, FERHATOĞLU FERHAT (2022). Completion Lymph Node Dissection Is Unnecessary After Positive Sentinel Lymph Node in Melanoma — a Case Series Analysis. Indian Journal of Surgery, Doi: 10.1007/s12262-022-03532-y

DOĞAN İZZET, GÜRBÜZ MUSTAFA, PAKSOY NAİL, FERHATOĞLU FERHAT, VATANSEVER SEZAİ, SAİP PINAR, DEMİRKAZIK AHMET, AYDINER ADNAN (2022). Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC. Medicine, 101(34), 30188, Doi: 10.1097/MD.0000000000030188

PAKSOY NAİL, KHANMAMMADOV NIJAT, DOĞAN İZZET, FERHATOĞLU FERHAT, YILDIZ ANIL, AK NAZİYE, AYDINER ADNAN (2022). Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study. Medicine, 101(45), 31726, Doi: 10.1097/MD.0000000000031726

PAKSOY NAİL, FERHATOĞLU FERHAT, DOĞAN İZZET, KHANMAMMADOV NIJAT, İRİBAŞ ÇELİK AYÇA, GÜLBAŞ ZAFER, BAŞARAN MERT (2022). High-dose chemotherapy followed by autologous stem cell transplantation for adult patients With first relapse of Ewing's sarcoma: A single institution experience. Medicine, 101(49), 32213, Doi: 10.1097/MD.0000000000032213

ÇİL İBRAHİM, KÜÇÜKARDA AHMET, ATCI MUHAMMED MUSTAFA, SECMELER SABAN, PAKSOY NAİL, FERHATOĞLU FERHAT, AK NAZİYE, AYHAN MURAT, TATAROĞLU ÖZYÜKSELER DENİZ, ÖNDER ARİF HAKAN, AVCI OKAN, OYMAN ABDİLKERİM, OKTEN ILKER NIHAT, GÜLTÜRK İLKAY, AKAGÜNDÜZ BARAN, BASOĞLU TÜYLÜ TUĞBA, ÇAKIR EMRE, HACIBEKİROĞLU İLHAN, ÖZÇELİK MELİKE, AYDINER ADNAN (2022). Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori Journal, 108(1), 19-25., Doi: 10.1177/03008916211037739

DOĞAN İZZET, KARABULUT SENEM, TAŞTEKİN DİDEM, FERHATOĞLU FERHAT, PAKSOY NAİL, ŞAKAR BURAK (2022). Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer. Journal of the College of Physicians and Surgeons Pakistan, 32(8), 1014-1019., Doi: 10.29271/jcpsp.2022.08.1014

FERHATOĞLU FERHAT, TUĞCU MURAT, APAYDIN SÜHEYLA (2022). Factors Affecting Postoperative Morbidity and Mortality in Chronic Hemodialysis Patients. Eurasian Journal of Medical Advances, 2(3), 30-38., doi: 10.14744/ejma.2022.43153

KAPAĞAN TANJU, FERHATOĞLU FERHAT, RETIRED SELİNAY, KILIÇ ÇAĞLA ECEM (2022). Risk Factors for Cutaneous Melanomas and Level of Awareness in Society. Journal of the Turkish Academy of Dermatology, 16(4), 94-100., Doi: 10.4274/jtad.galenos.2022.30092

FERHATOĞLU FERHAT, ALTAN FERHATOĞLU ZEYNEP (2022). Frequency, Demographic and Clinicopathological Characteristics of Skin Cancer Patients Treated and Followed Up in the Medical Oncology Outpatient Clinic. Journal of the Turkish Academy of Dermatology, 16(4), 77-81., Doi: 10.4274/jtad.galenos.2022.04706

KARABULUT SENEM, DOĞAN İZZET, USUL AFŞAR ÇİĞDEM, KARABULUT MEHMET, KARAMAN ŞULE, FERHATOĞLU FERHAT, TAŞTEKİN DİDEM (2021). Does nutritional status affect treatment tolarability, response and survival in metastatic colorectal cancer patients? Results of a prospective multicenter study. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 27(6), 1357- 1363., Doi: 10.1177/1078155220959427

AK NAZİYE, ÖZKAN BERKER, YENİGÜN BÜLENT MUSTAFA, YILMAZBAYHAN EMİNE DİLEK, TOKER SEYFİ ALPER, FERHATOĞLU FERHAT, YAŞAR HATIME ARZU, DİZBAY SAK SERPİL, TANJU SERHAT, DILEGE MUSTAFA ŞÜKRÜ, ERUS SUAT, BULUTAY PINAR, FIRAT PINAR, MANDEL NİL MOLİNAS, KILIÇKAP SAADETTİN, ONDER SEVGEN, DİKMEN ERKAN, ALAN ÖZKAN, YUMUK PERRAN FULDEN, BOZKURTLAR EMİNE, LAÇİN TUNÇ, YILDIZELİ BEDRETTİN, ÖZTÜRK AKIN, KOCATÜRK CELALETTİN İBRAHİM, KARAPINAR KEMAL, ÜRER HALIDE NUR, OYAN ULUÇ BAŞAK, AYDINER ADNAN, DEMİRKAZIK AHMET, ERALP YEŞİM (2021). The role of adjuvant chemotherapy in resected stage I non-small cell lung cancer: A Turkish Oncology Group Study.. Journal of BUON, 26(3), 819-829.

AK NAZİYE, TOKER SEYFİ ALPER, KARA MURAT, ÖZKAN BERKER, ÜLKER MELİKE GÜLER, KABA ERKAN, YEGEN GÜLÇİN, KARAMAN ŞULE, DAĞOĞLU SAKİN RABİA NERGİZ, KAYTAN SAGLAM ESRA, ORAL ETHEM NEZİH, KİZİR AHMET, BAYRAKTAR SOLEY, DİSTÇİ RIAN, FERHATOĞLU FERHAT, AYDIN ESRA, VATANSEVER SEZAİ, ERALP YEŞİM, AYDINER ADNAN (2021). Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center. TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 29(4), 487- 495., Doi: 10.5606/tgkdc.dergisi.2021.20529

AK NAZİYE, PAKSOY NAİL, FERHATOĞLU FERHAT, AYDIN ESRA, DOĞAN İZZET, BEKTAŞ ERDEM, KARACA MERT, OGUZ SOYDİNÇ HİLAL, MINARECİ YAĞMUR, SÖZEN HAMDULLAH, TOPUZ SAMET, SAİP PINAR MUALLA, VATANSEVER SEZAİ (2021). Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma. TURKISH JOURNAL of ONCOLOGY, 36(4), 438-445., Doi: 10.5505/tjo.2021.2882

Dr. Hossein Taghizadeh is a highly regarded Austrian specialist in internal medicine, hematology, and medical oncology, known for his compassionate approach and commitment to personalized cancer care. With extensive experience in treating solid tumors and blood cancers, he represents a new generation of oncologists who integrate scientific progress with empathy and precision.

He studied medicine at the Medical University of Vienna, graduating in 2016, and began his residency in internal medicine and oncology shortly thereafter. His academic and clinical training at leading Austrian cancer centers equipped him with deep expertise in systemic cancer therapy, hematologic diseases, and palliative medicine.

2010–2016 – Studied medicine at the Medical University of Vienna.

2018 – Began residency in internal medicine and medical oncology, focusing on individualized treatment strategies.

2020s – Specialized in solid tumors, hematologic malignancies, and targeted therapy, contributing to multidisciplinary oncology care.

Today – Practices as an oncologist at Oncodoc and Wiener Privatklinik, providing diagnostics, systemic treatment, and follow-up for patients with gastrointestinal, urogenital, and hematologic cancers.

Dr. Taghizadeh’s clinical interests include gastrointestinal tumors, pancreatic and biliary cancers, genitourinary malignancies, and hematologic neoplasms. He works with advanced diagnostic tools and modern systemic therapies, including chemotherapy, targeted therapy, and immunotherapy.

Known for his calm professionalism, integrity, and patient-centered communication, Dr. Taghizadeh places great emphasis on evidence-based medicine and emotional support throughout the treatment journey. His work reflects a modern, holistic approach to oncology — one that values both medical excellence and the human experience behind every diagnosis.

Dr. Christiane Thallinger is an Austrian dermatologist and venereologist. She focuses on skin cancer and oncologic dermatology. She began her medical career in 1999. She completed dermatology training at the Medical University of Vienna. She later served as a senior physician in its Department of Dermatology.

Her expertise includes diagnosis and treatment of melanoma, basal cell carcinoma, and squamous cell carcinoma. She performs dermatosurgery, cryotherapy, and photodynamic therapy. She also manages skin side effects caused by cancer treatment.

She is active in patient care and academic research. She is recognized for her patient-centered approach and for advancing dermatologic oncology in Austria.

Dermatologist

Univ.-Prof. Dr. Wolfgang Johannes Köstler is a board-certified specialist for Internal Medicine, Hematology/Oncology, and Intensive Care Medicine who specializes in hematology & internal oncology, intensive care medicine. He is one of the top-rated breast cancer and sarcoma oncologist specialists and has extensive experience in the field and has received degrees from the Medical University of Vienna and the Weizmann Institute of Science. He has also had special training at Memorial Sloan-Kettering Cancer Center and Royal Prince Alfred Hospital.

Professor, Oncologist

Professor Shlomi Constantini is a highly-trained neurosurgeon in Israel with expertise in general and pediatric neurosurgery, microsurgical operations, reconstructive interventions, and brain and spine tumor treatments. He has received several awards and is a member of multiple professional organizations.

Prof. Jack Baniel is a Professor of Urology and Chief of Urology section at Rabin Medical Center, Petach Tikva, Israel. He specializes in the reconstruction of the bladder, robotic prostatectomy, cancer surgeries with preservation of the nerve endings. He has published over 100 scientific articles and is actively involved in research in the field of uro-oncology. He is a graduate of Tel Aviv University and is a member of various professional organizations, including the Israeli Medical Association, the Israeli Association of Urology, the European Association of Urology, the European Organization for Research and Treatment of Cancer (EORTC), and the American Association of Urology.

Professor Dan Grisaro is a leading Israeli specialist in gynecological cancer diagnosis and treatment, specializing in ovarian cancer, uterine cancer, and cervical cancer. He has senior physician, head of department and lecturer experience at various medical centers and universities. He has held 39 presentations and is the author of 83 published scientific articles, and is a member of various professional societies.

EXPERIENCE

2024 - Present, Istanbul, Turkey

MEMORIAL ATAŞEHİR HOSPITAL

Medical Oncology Specialist

2016 - 2024, Istanbul, Turkey

MARMARA UNIVERSITY PENDIK TRAINING AND RESEARCH HOSPITAL

2015 - 2016, Kocaeli, Turkey

KOCAELİ STATE HOSPITAL

Compulsory Service

2011 - 2014, Istanbul, Turkey

DR. LÜTFİ KIRDAR TRAINING AND RESEARCH HOSPITAL

2010 - 2011, Sinop, Turkey

SİNOP DURAĞAN STATE HOSPITAL

Compulsory Service

2004 - 2010, Istanbul, Turkey

ISTANBUL UNIVERSITY CERRAHPAŞA FACULTY OF MEDICINE

EDUCATION

2020 - Present

Marmara University Pendik Training and Research Hospital

Associate Professorship in Medical Oncology

2011 - 2014, Istanbul, Turkey

Dr. Lütfi Kırdar Training and Research Hospital

Medical Oncology Specialization

2004 - 2010, Istanbul, Turkey

Istanbul University Cerrahpaşa Faculty of Medicine

Internal Medicine Specialization

1997 - 2003, Istanbul, Turkey

Istanbul University Cerrahpaşa Faculty of Medicine

Medical Education

SCIENTIFIC PUBLICATIONS

• 63 articles published in journals indexed in international databases (first author in 11 of them).

• Over 100 presentations at international and national congresses.

• 4 review articles published in national journals (first author in 3 of them).

• Authorship of 1 book chapter and co-editorship of 1 book.

Coping with gastrointestinal and lung cancer without chemotherapy. Specialists at the Tel Aviv Sourasky Clinic (Ichilov) use an ultra-modern innovative method to combat neuroendocrine tumors. It is based on radionuclide therapy with the radioisotope Lutetium 177 (Lutetium-177). This innovation is a real breakthrough in oncotherapy, because in recent decades the number of cases of this type of cancer has been rapidly growing.

This method is completely new in the world. Today it exists only in Israel, Germany and Sweden.

Its essence is in the use of a new radiopharmaceutical - Lutetium 177 PRRT. The drug is administered intravenously at intervals of 7-8 weeks. With the help of Lutetium, cancer cells are destroyed selectively, without affecting healthy tissues of the body. That is, this method of treatment can literally be called "local radiation therapy". In addition, the drug does not have a toxic effect on the bone marrow and kidneys, destroying the tumor from the inside.

In addition, the use of this method allows patients to avoid severe side effects of chemotherapy, such as vomiting, nausea, pain, alopecia, weakness. It is also important that the treatment is carried out by a special group of medical specialists. Among them: leading doctors, nurses and medical physicists!

All of them work under the supervision of Dr. Inna Ospovat, a leading specialist in the nuclear therapy department at the Ichilov Clinic.

Education

2000-1994 Faculty of Medicine in Vitebsk, Belarus.

Specialization

2003 - 2011 - specialization in oncology and radiation therapy at the Hadassah University Hospital in Jerusalem.

Recognized experience

Oncology and radiation therapy

Additional education

2015 - PMH University Hospital (Totonto) Childhood irradiation and head and neck tumors

Attending conferences

About 10 presentations at medical conferences

Trade union membership

• Israel Society of Clinical Oncology and Radiotherapy ISCORT
• American Association of Radiation Therapy ASTRO
• Israel Head and Neck Oncology Association
• Areas of special interest and activities
• Radiation therapy in children
• Radiobiological treatment PRBT
• Radiation therapy for gastrointestinal tumors
• Treatment of head and neck tumors and skin tumors